SAN RAMON, CALIF., October 11, 2022—With support from CooperVision, a global leader in myopia management, the University of Alabama at Birmingham (UAB) School of Optometry has named Adam Gordon, OD, MPH, FAAO, as the CooperVision Endowed Faculty Scholar in Myopia Control and Contact Lenses. This new faculty position empowers Dr. Gordon to explore related topics of his choice and collaborate with scholars and industry partners around the world.
Dr. Gordon, who is a Professor of Optometry, Director of the Cornea and Contact Lens Service at UAB Eye Care, and Chair of the School’s Department of Optometry and Vision Science, is committed to all aspects of cornea and contact lenses, but has special interests in myopia control and the use of medically necessary contact lenses for patients with keratoconus, post-surgical conditions and ocular surface diseases.
“This is an incredible honor, and I am humbled to be the first CooperVision Endowed Scholar at the UAB School of Optometry,” Dr. Gordon said. “I am grateful for the opportunity to hold this position and continue to work with talented faculty, students, residents, and staff. This generous endowment from CooperVision is an investment in the future of contact lens and myopia management education, research, and patient care at the School.”
“When I graduated from the UAB School of Optometry in 1982, I could not have envisioned that myopia would reach global epidemic status and be a major cause of visual impairment and morbidity worldwide,” he shared.
CooperVision and the UAB School of Optometry celebrated the appointment at a dedication event earlier this month, following the announcement of the gift this past spring. In addition to the endowed faculty scholar position, CooperVision’s support extends to research awards for students earning dual doctorate of optometry and master of vision science degrees and practicing optometrists pursuing a doctorate in vision science and conducting research in contact lenses and/or myopia management.
“We’re grateful to the UAB School of Optometry for how the institution is shaping the future of eye care through research and education,” said Michele Andrews, OD, Vice President, Professional & Government Affairs, Americas, CooperVision. “As we address difficult vision challenges, such has childhood myopia, we’re committed to supporting the future of the profession and the foundation of evidence-based care.”
# # #
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Hannah Barry, Counselor, McDougall Communications
firstname.lastname@example.org or +1-585-645-8985